Through both direct and indirect actions on multiple aspects of the detrimental transformation of EAT, GLP-1 and dual GLP-1/GIP receptor agonists offer a novel approach to obesity treatment that may influence metabolic pathways leading to obesity-related cardiomyopathy. This evidence concerns the gene GLP1R and cardiomyopathy.